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Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common red cell enzyme defect, affecting about 400 million people worldwide [1]. The prevalence 
of G6PD deficiency in India ranges from 2% to 27%, the most 
common variant being G6PD Mediterranean [2]. G6PD is a house 
keeping enzyme and critical in redox metabolism of all aerobic 
cells, more importantly erythrocytes as they do not have an alternate 
pathway of nicotinamide adenine dinucleotide phosphate hydrogen 
(NADPH) generation. Neonatal hyperbilirubinemia is one of its 
most common presentations of G6PD deficiency [3]. About 10-50% 
of the deficient neonates are affected, requiring phototherapy, and 
often exchange transfusion [4]. In the neonatal period, hemolysis 
may be precipitated in the absence of an obvious trigger [5]. Despite 
extensive literature review, sparse reports exist on the naphthalene 
triggered hemolysis in neonates. We present a case of a G6PD 
deficient male neonate with exposure to naphthalene, presenting 
with severe hemolysis requiring exchange transfusion.
CASE REPORT
A male baby was born to a booked and immunized 25-year-
old primigravida female with term gestation without any sepsis 
setting. Baby cried immediately after birth, weighed 2500 g and 
given Vitamin K 1 mg at birth. Breastfeeding was initiated and the 
baby was transferred to the mother in postnatal ward. The first 24 
h of life were uneventful; the baby passed urine and stool and was 
accepting breastfeeds well. At 42 h of life, the baby was icteric till 
abdomen with transcutaneous bilirubin 13 mg/dl. There was no 
pallor, bruising, cephalhematoma, or hepatosplenomegaly.
Phototherapy was started and the baby was investigated. The 
maternal blood group was O+ve, baby’s blood group was O˗ve, 
direct Coombs test: Negative, total serum bilirubin: 13.8 mg/dl 
(direct: 1.9 mg/dl and indirect: 11.9 mg/dl) and hemoglobin (Hb): 
14.1 g/dl. Despite effective phototherapy (light emitting diodes), 
at 54 h of life, the baby presented with features of acute hemolysis: 
Deep icterus till soles, pallor and hepatosplenomegaly. The baby 
underwent double volume exchange transfusion uneventfully, 
and phototherapy was continued.
The pre-exchange serum bilirubin was 28 mg/dl (direct: 
2.6 mg/dl and indirect: 25.4 mg/dl), Hb: 7 g/dl, hematocrit: 19.9%, 
and reticulocyte count: 12%. The peripheral smear was suggestive 
of anisopoikilocytosis, polychromatic, few nucleated cells without 
any sphere, or elliptocytes. The renal function tests including serum 
electrolytes were within normal range; sepsis screen and blood culture 
were negative. The post-exchange serum bilirubin was 10.9 mg/dl, 
Hb: 14.3 g/dl, and hematocrit 42%. All other investigations were 
within normal limits. The serum bilirubin declined to below 
phototherapy levels in 2 days, and the baby was accepting well orally. 
The baby’s pre-exchange G6PD level was 9.1 U/g Hb (normal value 
for neonate: >14 U/g Hb by enzymatic flour immunoassay). There 
was no history of intake of oxidant drugs by either mother or baby.
On retrospectively reviewing the history, we found that after 
birth, the baby was wrapped in sheets and made to wear clothes 
kept in the cupboard with naphthalene balls. Later, samples for 
G6PD levels were sent to the mother, and found be 14 U/g Hb 
(normal value for adult: >20 U/g Hb); although, G6PD level of 
maternal uncle was normal.
DISCUSSION
G6PD is an X-linked recessive enzymopathy, critical in the redox 
metabolism in all aerobic cells as it maintains glutathione in the 
ABSTRACT
Glucose-6-phosphate dehydrogenase (G6PD), a critical enzyme in the hexose monophosphate pathway, is a key component in 
the antioxidant mechanism of all cells, particularly erythrocytes. Its deficiency may manifest in the neonatal period in the form 
of severe hyperbilirubinemia. Hemolysis in neonate may occur de novo or be precipitated by stressors such as oxidant drugs or 
naphthalene. We report a case of 3 days old, G6PD deficient neonate, with naphthalene induced hemolysis, requiring exchange 
transfusion.
Key words: Deficiency, G lucose-6-phosphate dehydrogenase, Hemolysis, Hyperbilirubinemia, Naphthalene, Oxidants
Vol 4 | Issue 4 | Oct - Dec 2017 Indian J Child Health 630
Kamal et al. Naphthalene induced haemolysis
reduced form which helps to combat oxidant stress. Its deficiency 
has predominantly hematological manifestations as it is the only 
source of NADPH in erythrocytes. The disease is expressed in 
heterozygous males and homozygous females, while heterozygous 
females may have an intermediate expression. Its geographical 
distribution coincides with endemic malaria worldwide. In India, 
Punjab, Orissa, parts of West Bengal, Andhra Pradesh, and Kerala 
contribute to majority of the cases.
Hyperbilirubinemia in G6PD deficient neonates is a well-
documented entity [6]. In addition to defective glucuronidation 
and hemolysis, coinheritance of uridine diphosphate-
glucornyltransferase-1 deficiency of Gilbert’s syndrome and pregnant 
women ingesting oxidant drugs are implicated in the pathogenesis of 
jaundice [1]. The damage starts in utero but clinically manifests at 
day 2 or 3 of life. In a recent study conducted in India in 2015, 13.3% 
of the all jaundiced neonates are G6PD deficient, of which 12% were 
females [7]. Prematurity, sepsis, asphyxia, and major and minor 
blood group incompatibilities are compounding factors leading to 
severe hyperbilirubinemia [5]. However, none of these factors were 
present in our case. Certain G6PD mutation variants, seen in some 
racial groups increase the susceptibility to severe hemolysis and have 
higher rates of bilirubin encephalopathy and death [8,9].
Apart from exposure to oxidant drugs or maternal intake 
of such drugs during pregnancy, ingestion of fava beans and 
exposure to naphthalene balls are well documented to trigger 
hemolysis in such cases [10]. On reviewing the history with the 
parents, we found exposure to naphthalene in this case, starting 
from day 1. Hyperbilirubinemia may also appear in the absence of 
hemolysis triggering factors, especially in neonates [11]. A similar 
case was reported from Panama, where a 4 days old term neonate, 
who presented with jaundice, generalized tonic clonic seizures, 
required management with anticonvulsants, phototherapy, 
and exchange transfusion. A history of using naphthalene 
impregnated garments was recorded [12]. Valaes et al. also 
reported 21 neonates who developed hemolysis after exposure to 
naphthalene, 12 of whom were found be to G6PD deficient [13]. 
Newborns are unable to conjugate naphthalene metabolites, have 
thinner skin; oil massage also enhances absorption as naphthalene 
is lipophilic [14]. Phototherapy and exchange transfusion are the 
mainstay of management in jaundiced neonates.
Affecting about 5% of the world population, G6PD deficiency 
is not a rare entity and is easily preventable by avoidance of 
few triggers. In addition, avoidance of exposure to oxidant 
drugs if any, blood transfusion for severe anemia and folic acid 
supplementation play an important role. Repeat G6PD assay 
should be performed 3 months later in case of doubtful results. 
WHO recommends routine screening in populations in which 
3-5% or more males are G6PD deficient [15]. G6PD deficiency 
should be considered with a high index of suspicion in cases who 
develop jaundice in the first 24 h of life, history of jaundice in a 
sibling, bilirubin levels >95th percentile, and in Asian males [16].
CONCLUSION
G6PD deficiency may manifest in the neonatal period in the 
form of severe hyperbilirubinemia. Hemolysis in neonate may 
be precipitated by stressors like naphthalene; therefore, careful 
history is very important to reach the diagnosis and to manage 
such cases.
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